Adaptive Biotechnologies (ADPT) Income Statement

Click line-items for a historical chart and %

Revenues	24.65M
Cost of revenues (inclusive of amortization and impairment of acquisition-related intangible assets)	19.95M
Gross margin	4.69M
Operating expenses:
Research and development
Selling, marketing and administrative	9.3M
Amortization of acquisition-related intangible assets
Restructuring charges
Impairment of long-lived assets
Total operating expenses	36.9M
Operating loss	-32.21M
Interest and other income, net
Income (loss) from continuing operations before income taxes
Benefit from (provision for) income taxes	2.06M
Income (loss) from continuing operations, net of taxes
Income (loss) from discontinued operations, net of taxes
Gain on disposal of discontinued operations, net of taxes
Income from discontinued operations, net of taxes
Net income (loss)	-65.15M
Basic
Income (loss) from continuing operations, net of taxes (in Dollars per share)
Income from discontinued operations, net of taxes (in Dollars per share)
Net income (loss) (in Dollars per share)	-5.69
Diluted
Income (loss) from continuing operations, net of taxes (in Dollars per share)
Income from discontinued operations, net of taxes (in Dollars per share)
Net income (loss) (in Dollars per share)	-5.69
Shares used in computing income (loss) per share:
Basic (in Shares)	-23.01M
Diluted (in Shares)	-23.01M

Entities mentioned with ADPT